The global lipid nanoparticle (LNP) contract development and manufacturing organization (CDMO) market is entering a new phase of growth as pharmaceutical and biotechnology companies seek manufacturing partners capable of supporting therapies from clinical development through commercial production.
According to Medi-Tech Insights, the LNP CDMO market is projected to expand at approximately 14% CAGR through 2031. While commercial manufacturing currently accounts for the largest revenue share, clinical-stage services are expected to grow fastest, underscoring the need for integrated development, process optimization, and manufacturing capabilities.
A recent investment by Evonik in Vancouver, Canada, illustrates how CDMOs are positioning themselves to address these evolving requirements.
Evonik Invests More Than C$150 Million in Vancouver GMP Facility
In August 2026, Evonik announced an investment of more than C$150 million to establish a new good manufacturing practice (GMP) facility in Vancouver, strengthening its capabilities in lipid-based drug delivery and advanced pharmaceutical manufacturing.
The project is supported by up to C$68 million in funding from the Canadian government’s Strategic Response Fund. According to Evonik, the new facility is designed to provide more than three times the manufacturing capacity of its existing Vancouver operation for advanced pharmaceutical products. It will also expand quality-control and microbiological testing capabilities.
Drug product production at the new facility is planned to begin by the end of 2029. The investment is intended to support pharmaceutical and biotechnology customers developing mRNA therapeutics, vaccines and other lipid-based medicines, including products that use LNP delivery systems.
The expansion reflects a broader industry priority: building manufacturing infrastructure to support early-stage development while preparing promising therapies for large-scale production. https://www.evonik.com/en/news/press-releases/2026/08/evonik-expands-lipid-based-drug-delivery-capabilities-with-new-gmp-manufacturing-facility-in-vancouver-canada.html
Clinical Development and Commercial Manufacturing Drive Market Demand
LNP technology plays an important role in delivering nucleic acid-based therapeutics, including messenger RNA (mRNA) and other genetic medicines. As developers explore additional applications, manufacturing requirements are becoming more complex.
The projected growth of clinical-stage services creates opportunities for CDMOs to support formulation development, process characterization, analytical testing, and GMP production for clinical trials. These capabilities help developers generate the manufacturing and quality data needed as candidates progress through development.
Commercial manufacturing presents a different set of requirements. Customers need consistent product quality, validated processes, dependable production schedules, and the ability to maintain supply as demand increases.
For CDMOs, the challenge is to connect these two stages without introducing unnecessary delays, process variability, or technology-transfer risks.
The coexistence of a large commercial manufacturing segment and rapidly growing clinical-stage services suggests that companies capable of supporting multiple development milestones may be better positioned to build long-term customer relationships.
Manufacturing Scale Is Only One Part of the Competitive Equation
Capacity expansion is an important element of LNP manufacturing strategy, but physical infrastructure alone does not determine a CDMO’s competitive position.
LNP production requires coordination across lipid selection, formulation development, process engineering, analytical characterization and quality management. Manufacturers must also address process reproducibility, batch consistency and the requirements associated with transferring processes between development and commercial production.
These capabilities become particularly important when a therapy advances from small clinical batches to larger production volumes. A process that performs successfully at an early stage may require further optimization to maintain product characteristics and manufacturing consistency at commercial scale.
Integrated service offerings can help reduce the complexity of managing multiple development and manufacturing partners. However, the value of integration depends on demonstrated technical capabilities, appropriate quality systems, and the ability to meet individual customer requirements.
Evonik’s Vancouver investment combines expanded manufacturing infrastructure with additional quality-control and testing capabilities, addressing several elements of this development-to-commercialization pathway.
Competitive Landscape: Key Companies in the LNP CDMO Market
Competition in the LNP CDMO market includes organizations with expertise across pharmaceutical development, lipid manufacturing, formulation services, and large-scale contract manufacturing.
Key companies identified for the competitive landscape include:
- Merck Group
- Evonik
- Corden Pharma
- Catalent
- Lonza
- FUJIFILM Pharmaceuticals U.S.A., Inc.
- Samsung Biologics
- Curia Global
- Ardena
- Curapath
These companies have different service portfolios, manufacturing footprints, and areas of technical specialization. Their competitive positions should therefore be evaluated based on the specific services they offer, rather than treating all participants as interchangeable LNP manufacturing providers.
For pharmaceutical and biotechnology companies, partner selection may depend on the candidate’s development stage, the type of lipid delivery system, the required production scale, regulatory expectations, and geographic supply considerations.
For CDMOs, opportunities may arise from strengthening specialized formulation expertise, expanding GMP capacity, improving analytical services or building partnerships that support a more continuous development-to-commercialization process.
Strategic Implications for CDMO Investment
The market’s projected growth creates several strategic considerations for manufacturing service providers.
1. Align capacity investment with customer development pipelines. Expansion decisions should consider expected demand across clinical and commercial stages, including the timing of potential customer programs and the production requirements of individual modalities.
2. Strengthen analytical and quality capabilities. Testing, process characterization and quality-control infrastructure can be important differentiators when customers evaluate manufacturing partners for complex pharmaceutical products.
3. Reduce clinical-to-commercial transition risks. Technology transfer, process reproducibility and scale-up expertise can influence how efficiently a program advances between development milestones.
4. Build specialized rather than undifferentiated capacity. CDMOs may benefit from investments that address identifiable customer requirements, such as lipid-based formulation expertise, specialized testing or integrated GMP manufacturing services.
5. Evaluate long-term supply reliability. Manufacturing location, operational resilience, quality systems and the ability to maintain consistent production schedules should remain central to partnership and sourcing decisions.
These priorities do not eliminate the financial and execution risks associated with capacity expansion. New facilities require substantial capital, skilled personnel, regulatory readiness, and sufficient customer demand to support utilization. The timing of clinical progress and commercial approvals can also affect how quickly new infrastructure generates returns.
Outlook: Integrated Capabilities May Shape Future Competition
The LNP CDMO market’s expected growth through 2031 points to opportunities across both clinical development and commercial production. However, the most important competitive distinction may be the ability to connect these stages through reliable processes, strong analytical capabilities and scalable manufacturing infrastructure.
Evonik’s Vancouver expansion is one example of how a CDMO is investing in this transition. Its long-term impact will depend on execution, customer demand and the successful commissioning and operation of the new facility.
For the wider industry, the strategic question is increasingly clear: how can manufacturers invest in capacity and specialized expertise while maintaining the quality, consistency and reliability required to support advanced therapies?
As LNP applications evolve, companies that align manufacturing investment with demonstrable customer needs and technical capabilities will be better positioned to evaluate opportunities across the development and commercialization pathway.
Explore the LNP CDMO market and competitive landscape: https://meditechinsights.com/lipid-nanoparticles-cdmo-market/request-sample
clinical-to-commercial scale-up
Jeff Berman is a healthcare and medical technology journalist with over 7 years of experience covering the global medtech, biotechnology, pharmaceutical, and healthcare sectors. As a contributor to Just MedTech, he specializes in industry news, market trends, regulatory developments, mergers and acquisitions, and emerging innovations shaping the future of healthcare worldwide. Contact: jeff.b@justmedtech.com.